be noted that all AAs do have a risk of metabolic syndrome, and patients should be monitored appropriately while receiving these medications.
Overall, AAs can be beneficial in alleviating behavioral symptoms, and should be considered an appropriate therapeutic option, as part of a comprehensive treatment strategy, for children with PDD.
Pervasive developmental disorders (PDDs) are some of the This article reviews the data available on the use of atypical antipsychotics (AAs) in children and adolescents with PDD, and most intriguing, fascinating, and puzzling childhood disorders. discusses the possible relationship between AA pharmacology and The five disorders encompassed under PDDs are: (i) autistic the neurochemical aspects of PDDs; the epidemiology, etiology disorder; (ii) Asperger's disorder; (iii) childhood disintegrative and comorbidity associated with PDDs are also discussed. A disorder; (iv) Rett's disorder; and (v) PDD -not otherwise speci-MEDLINE search (1988-January 2007) was conducted to find fied (PDD-NOS). [1] PDDs are neurobehavioral syndromes marked published reports regarding the use of AAs in PDDs. Keywords by qualitative impairments of social interaction and communicaused were 'autism,' 'PDD,' 'risperidone,' 'olanzapine,' 'quetion, and restricted, repetitive, and stereotypic patterns of behavtiapine,' 'ziprasidone,' 'aripiprazole,' 'clozapine,' and 'Asior. [2] PDDs are spectrum disorders. Each disorder is defined by a perger's.' Also, the references of the articles found were reviewed specific set of behaviors in the areas of social skills, communicafor other reports. All published, open-label, and double-blind tion deficits, and stereotypic behavior; however, individuals withstudies in patients with PDDs aged ≤18 years were included. The in the spectrum can exhibit any combination of these behaviors in PDDs included autistic disorder, Asperger's disorder, childhood various degrees of severity. [1, 3] A more detailed description of the disintegrative disorder, and PDD-NOS. Retrospective chart rebehavior exhibited by individuals with each of these disorders is views and case reports were excluded, except those for clozapine presented in table I.
(there were only two published case reports in the literature). The defining characteristics of autistic disorder that differentiate it from other disorders in the spectrum are substantial qualita-1. Epidemiology, Comorbidity and Etiology tive impairment of social interaction, greater qualitative impairment of communication, and restricted, repetitive, and stereotypic patterns of behavior, interests, and activities. These three defining
Prevalence
features are present before the age of 3 years. [1, 3, 4] The incidence of individuals diagnosed under the umbrella of The key essential characteristics of Asperger's disorder are PDDs in the US population continues to increase. Recent data severe and sustained deficits in social interaction as well as refrom the Centers for Disease Control Prevention show that up to 1 stricted repetitive patterns of behavior, interests, and activity.
in 166 individuals in the US will be diagnosed with one of the Unlike autistic disorder, individuals with Asperger's disorder do PDDs. [7] PDD-NOS is more common with a prevalence rate of 1 not present with significant delays in language, cognitive, or selfper several 100 children. [8] This higher incidence of PDD-NOS is help skills. [1, 3] partly due to the wide scope of its diagnostic criteria. [1] Rett's In terms of language development differences, the main differdisorder and childhood disintegrative disorder are much rarer. The ence between individuals with autistic disorder and those with exact prevalence of Asperger's disorder is unknown, although it is Asperger's disorder is that the latter usually present with good commonly seen in clinical practice. The PDDs are four times more language skills, but have trouble understanding the subtleties of prevalent in males than in females, with the exception of Rett's language, such as irony and humor. [1] Both populations present disorder, which seems to occur exclusively in females. with deficits in their perspective taking and empathy skills. Just like children with autistic disorder, children with Asperger's disor-
Co-Existing Disorders
der are unable to comprehend what it means to interact with other people in an acceptable and appropriate manner. [5, 6] Other behavIndividuals with PDDs have a higher risk of certain co-existing iors emitted by individuals with Asperger's disorder are clumsidisorders, including attention-deficit disorder, congenital rubella ness, difficulty with fine-gross motor skills, preoccupation with syndrome, epileptic seizure, fragile X syndrome, learning disabilione's own interests, difficulty judging one's own space, difficulty ties, Tourette's disorder, and tuberous sclerosis. [3, 9] Additionally, understanding other people's feelings, and repetitive and stereoabout 20-30% of individuals with autism will develop epilepsy by typic behaviors. [3] the time they reach adulthood. [9] 
Proposed Etiology
that the inability to imitate gestures, a common deficit in individuals with PDDs, might be associated with dyspraxia, which would indicate abnormalities in frontal/parietal-subcortical circuits, Although the specific cause of each PDD is still unknown, there which are associated with the acquisition of the sensory represenis agreement that a PDD is the result of a neurologic disorder that tations of movement. [11] affects the normal functioning of an individual's brain, impacting upon their development in the social and communication skills
Past research has shown that brain scans show differences in areas. [5, 6, 10] Deficits in social cognition, central coherence, and the shape and structure of the brain of individuals with autism and executive function have been found in individuals diagnosed those without autism. [12] Current research continues to look at the within the PDD spectrum. [5, 6, 10] It is clear that there is a correlation role of heredity, genetics, and medical problems, as patterns of between PDDs and deficits in executive functions; however, it is PDDs or related disabilities in many families seem to support a not clear if these deficits cause the disorders, or if the disorders genetic basis to these disorders. More importantly, researchers are cause these deficits. [10] beginning to recognize that there might not be a single explanation It is important to note that individuals with injuries to the for these disorders. [13] Results of a recent study by Williams et frontal lobes of the brain as well as those with other development al. [14] suggest that autism might affect how the brain processes disabilities have also shown deficits in social cognition as well as information, making it more of a global disorder than a social executive function. [10] Finally, recent research seems to suggest interaction disorder. Furthermore, ongoing research is looking at the role of irregular segments of genetic code or other factors that Historically, conventional antipsychotics, such as haloperidol, might result in higher susceptibility to a diagnosis of PDD. [15] In have been used to treat children with PDDs. They have targeted addition, research continues to investigate the possibility that symptoms such as irritability, aggression, hyperactivity, stereotypunder certain conditions a cluster of unstable genes may interfere ic behavior, impulsivity, and social adaptation. [28, 29] However, with brain development resulting in one of the disorders in the their use in this population has been limited because of the high PDD spectrum. [16] incidence of movement disorders. With the introduction of atypical antipsychotics (AAs), which include risperidone, olanzapine, Additionally, other researchers are investigating other factors quetiapine, ziprasidone, aripiprazole, and clozapine, a new treatthat might play a role in the onset of PDDs, such as problems ment option for PDDs has emerged. However, this class of drugs during pregnancy or delivery and environment factors (i.e. viral does not come without their own risks, mainly weight gain and an infections, metabolic imbalances, exposure to environmental increased risk of metabolic syndrome. [30] chemicals). Exposure to certain chemicals during pregnancy has been suspected to cause an increased incidence of PDD; however, Risperidone was the first AA to be rigorously studied in PDDs initial research has not shown a definite link. [17] and has shown consistent efficacy. There is published trial data for the other AAs, but the evidence is not as extensive as with Although initial research seemed to point to a link between risperidone. vaccines and autism, [18] an investigation by a committee of the Institute of Medicine (Washington, DC, USA) in 2004 concluded
Efficacy of Atypical Antipsychotics
that the available data showed no clear relationship between the measles-mumps-rubella vaccine and autism.
[19] Furthermore, there
Risperidone
are data from different countries showing no relationship between vaccines and autism.
[20-22]
Double-Blind Studies
Data from the double-blind, placebo-controlled trials of risperidone in PDDs are summarized in table II and discussed in this 2. Pharmacotherapy and Educational/ section. For a more in-depth look at the risperidone studies reBehavioral Interventions viewed here the reader is referred to a recently written article. [31] Researchers and practitioners in the medical and education
The RUPPAN (Research Units on Pediatric Psychopharmacolfields agree that there is no cure for PDDs, and all pharmacotheraogy Autism Network) [32] conducted an 8-week study evaluating pies and other interventions are intended to address specific sympthe safety and efficacy of risperidone in autistic children with toms of the disorders. The majority of the professionals agree that serious behavioral disturbances. Inclusion criteria were a diagnoearly intervention is key.
[23] Since PDDs are spectrum disorders, sis of autistic disorder as defined in the Diagnostic and Statistical treatment should be tailored to each individual's specific deficits Manual of Mental Disorders, 4th edition (DSM-IV), as well as a and assets.
score of at least 18 on the irritability subscale on the Aberrant As outlined by the National Institutes of Health (Bethesda, MD, Behavior Checklist (ABC). The children must have also exhibited USA), evidence-based treatment strategies include the use of tantrums, aggression, self-injurious behaviors, or a combination of medications and education/behavior intervention.
[9] The use of these problems. A total of 101 patients were enrolled in this study; highly structured and intensive skill-oriented education practices 49 were assigned to risperidone (at 0.5 mg/day; final dose 1.8 ± 0.7 based on the principles of applied behavior analysis has been mg/day) and 52 were given placebo. Mental development was shown to help individuals with PDDs develop social and language stated for only 91 patients: 5 had average or above average IQ, 12 skills. [3, [24] [25] [26] A full review of behavior interventions is beyond the had a borderline IQ, 43 had mild or moderate retardation, and 31 scope of this article; the reader is referred elsewhere for such an had severe retardation. To determine the children's baseline sympoverview. [26, 27] toms, the Clinical Global Impressions -Severity (CGI-S) scale was implemented. At baseline, 18 children had a moderate severiAntidepressant medications are often prescribed to treat anxiety rating on the CGI-S, 55 had marked severity, 24 had severe ty, depression, and or obsessive-compulsive symptoms in patients impairment, and one was considered extremely impaired. Primary with PDDs. Antipsychotic medications are prescribed for those outcomes of this study were measured using the irritability subindividuals with several behavior problems, such as aggression scale of the ABC and the Clinical Global Impressions -Improveand irritability. Anticonvulsant medications are used to treat those ment (CGI-I) rating. individuals who present with seizures or mood disorders. Individuals who present with attention-deficit disorder characteristics are After 8 weeks of treatment, risperidone-treated patients had a often treated with stimulant medications.
significantly greater decrease in the mean irritability score com- [32, 33] 14.1% decrease with PLA (from 25.5 behavior ± 6.6 to 21.9 ± 9.5) [p < 0 [34] 8wk, db, pc RIS; 1.17 mg/d 79 (61); 5-12 Mean ABC irritability score: decrease Irritability, hyperactivity, (0.04 mg/kg/d) from 18.9 at baseline to 6.8 at study inappropriate speech, social endpoint with RIS vs decrease from withdrawal, stereotypic and 21.2 to 14.7 with PLA (p < 0.001) conduct behavior, anxiety, CGI-I: VMI or MI: n = 21 with RIS vs emotional sensitivity n = 7 with PLA (p < 0.001) Nagaraj et al. [35] 6mo, db, pc RIS; 0.5 mg/d for first 39 (34); 2-9 CARS: 12/19 RIS and 0/20 PLA pts Social responsiveness, non2wk and then 1 mg/d improved by ≥20% from baseline verbal communication, for subsequent period (p < 0.001) hyperactivity, aggression, CGAS: 17/19 RIS and 2/20 PLA pts irritability improved by ≥20% from baseline (p = 0.035) Global Impression of Parents: with RIS 9/19 'improved to some extent;' 9/19 'considerably improved;' 1/19 worsened with PLA 6/20 'improved to some extent;' 9/20 'no change;' 4/20 worsened Troost et al. [36] Phase Luby et al. [37] 6mo, db, pc RIS; 1.14 mg/d 23 (17); 2.5-6 CARS: RIS -4.6, PLA -1.8
No specific symptoms (range: 0.5-1.5 mg/d) (p = 0.114) improved over placebo
Hollander et al. [38] 8wk, db, pc OLZ; 10 mg/d 11 (9); 6-14 CGI-I VMI/MI: OLZ 3/6, PLA 1/5 Global functioning; no (range: 7.5-12. pared with placebo recipients (from 26.2 ± 7.9 to 11.3 ± 7.4 and A separate report by Aman et al. [39] specifically focused on the from 25.5 ± 6.6 to 21.9 ± 9.5; p < 0.001). Also, 75.5% of acute and long-term safety and tolerability of risperidone in the risperidone-treated patients had a rating of 'much improved' or RUPPAN study.
[32] The short-term, double-blind study safety re-'very much improved' on the CGI-I, whereas only 11.5% of sults, as well as the open-label extension and discontinuation placebo patients had these ratings (p < 0.001). A positive response phase results were included in this examination. [33] Adverse effects was defined as having at least a 25% improvement on the irritabilithat were significantly more prevalent in the risperidone-treated ty subscale, as well as having a rating of 'much improved' or 'very group were as follows: tiredness during the day (p < 0.0001); much improved' on the CGI-I scale; 69% (34 of 49) of risperexcessive appetite (p < 0.0001); difficulty waking (p < 0.05); idone-treated patients had a positive response, compared with only excessive saliva or drooling (p = 0.04); and dizziness or loss of 11.5% (6 of 52) placebo patients (p < 0.001). In the risperidonebalance (p = 0.04). However, risperidone-treated patients had treated group, the adverse effects with the highest incidence rate fewer occurrences of anxiety (p = 0.05) and problems falling were weight gain, increased appetite (73%), fatigue (59%), and asleep (p = 0.02) than the placebo group. In the acute phase, drowsiness (49%). The average weight gain in risperidone-treated risperidone-treated patients had an average increase in sleep time patients was 2.7 ± 2.9kg compared with 0.8 ± 2.2kg for placebo of 40 minutes, compared with only a 17-minute increase for recipients (p < 0.001). No extrapyramidal symptoms (EPS) were placebo patients. There were no clinically significant changes in reported in either group. Three patients withdrew from the risperlaboratory values; however, fasting glucose and lipid values were idone group compared with 12 from the placebo group because of not mentioned. In accordance with other studies, [40] both body a lack of efficacy. No patients withdrew from either group because mass index and weight increased significantly with the use of of an adverse effect.
risperidone. This increase continued throughout the study, but gradually decelerated. Also, 82% of risperidone-treated patients After the original 8-week study period, placebo non-responders displayed an excessive appetite, compared with 38% of placebo were given the option to enter an 8-week open-label treatment patients. There were no differences between the groups in terms of period with risperidone. Patients that had a positive response heart rate, body temperature, or blood pressure throughout the during this phase, as well as those with a positive response during entire study. In reference to the Simpson-Angus rating scale and the initial 8-week double-blinded trial, were allowed to enter a 4-the AIMS, data failed to suggest that risperidone caused more EPS month open-label extension, with an additional 8-week doublethan placebo. However, benzatropine was given to one patient for blinded discontinuation phase. [33] Patients that entered the disconmotor restlessness, and at least one patient had dose-dependent tinuation phase either continued risperidone therapy or were gradcogwheel rigidity while taking risperidone. ually tapered off by 25% per week whilst given placebo. SixtyProlactin-related adverse events in the RUPPAN study were three patients entered the 4-month open-label phase. The irritabiliexamined in a separate publication. [41] Prolactin levels were two to ty subscale on the ABC and the CGI-I were again the primary four times higher in patients receiving risperidone versus placebo. outcome measures. The positive response definition in this phase Prolactin levels were assessed at baseline, 8 weeks, 6 months, and was the same as in the 8-week phase. Relapse was defined as a 22 months; the results with risperidone were 9.3 ± 7.5 ng/mL, 39.0 25% increase in the irritability subscale score, and a CGI-I rating ± 19.2 ng/mL, 39.0 ± 19.2 ng/mL, 32.4 ± 17.8 ng/mL, and 25.3 ± of 'much worse' or 'very much worse' in the discontinuation 15.6 ng/mL, respectively. The placebo results were 9.3 ± 7.6 ng/ phase. The maximum dosage during the 4-month open-label phase mL at baseline and 10.1 ± 7.8 ng/mL (p < 0.0001), at 8 weeks. was 3.5 mg/day for patients weighing 15-45kg and 4.5 mg/day for There were no prolactin-related adverse effects in the subset of 42 patients weighing >45kg. Fifty-one patients completed the openrisperidone recipients reviewed in this study. These results are label phase, and all of these patients maintained a positive reconsistent with previously reported data showing an initial insponse. The most common adverse effects were increased appecrease in prolactin levels with risperidone with a gradual decrease tite, sedation, and lethargy. Risperidone-treated patients experafterwards. [42] ienced an average weight gain of 5.1 ± 3.6kg over 6 months, which was significantly higher than that in placebo recipients (p < 0.001).
McDougle et al. [43] performed an analysis of the RUPPAN The Abnormal and Involuntary Movement Scale (AIMS) and the database [32] but focused on the core symptoms of autism (social Simpson-Angus scale showed no evidence of EPS or other neuroimpairment, lack of communication skills, stereotypic movelogic adverse effects. Of these 51 patients, 38 entered the disconments) instead of the maladaptive behaviors. The objective of this tinuation phase, and 32 completed it. This phase was terminated analysis was to determine if risperidone improved the core sympearly due to a high relapse rate in the placebo group (10 of 16); 2 of toms of autism. In order to ascertain this, a modified Ritvo-16 risperidone-treated patients also relapsed.
Freeman Real Life Rating Scale (R-FRLRS) and the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) were used. speech, lethargy/social withdrawal, and stereotypic behavior. RisThe modified R-FRLRS used the original subscales, but rephrased peridone-treated patients also showed improvement in the parentcertain words so that parents could use the scale. The five subrated Nisonger-Child Behavior Rating Form (N-CBRF) in regard scales were sensory motor behaviors, social relatedness, affectual to conduct problems (p ≤ 0.01), insecurity/anxiety (p = 0.039), reactions, sensory responses, and language. At week 8, risperidone hyperactivity (p = 0.035), and overly sensitive (p = 0.038) subwas more efficacious than placebo at improving the scores for the scales. In terms of the CGI-I, 21 risperidone-treated patients were sensory motor behaviors, affectual reactions, and sensory rerated as 'much improved' or 'very much improved' compared sponses subscales, as well as the overall scores. However, the with only seven patients in the placebo group. Seventy-one percent changes in two of the core areas, social relationships and language, of risperidone-treated patients reported having somnolence versus were not statistically significant. The CY-BOCS, which is normal-7.7% of placebo patients. The mean weight gain increase for ly used for obsessive-compulsive disorder, was modified to better risperidone-treated patients was 2.7kg versus 1kg in the placebo assess autism. The modifications made were to only include the group. Increased appetite, tachycardia, and increased systolic prescompulsion items and also to add autism-specific symptoms. At sure were also reported at a significantly higher incidence with week 8, the risperidone group improved on the CY-BOCS with risperidone than placebo. EPS were reported in eleven risperidonescores decreasing from 15.51 ± 2.73 to 11.65 ± 4.02 compared treated patients and five placebo-treated patients. For the risperwith the placebo group with scores decreasing from 15.18 ± 3.88 idone group, tremor and hypokinesia were the most common EPS. to only 14.21 ± 4.81 (p = 0.005).
Nagaraj et al. [35] conducted a 6-month, randomized, doubleYet another sub-analysis from the RUPPAN on the same pablind, placebo-controlled study to determine if risperidone can tient population showed significant improvement in communicaimprove the behavior, social, and emotional responsiveness, and tion socialization and in daily living skills for children receiving communication skills in children with autism. The researchers also risperidone compared with placebo based on the Vineland Adaprecorded the safety of risperidone throughout the trial. Participants tive Behavior scale. [44] all had a diagnosis of autism according to the DSM-IV. Patients with severe mental retardation or any significant coexisting disShea et al. [34] evaluated the safety and efficacy of risperidone in ease or illness were excluded. Risperidone was administered at 0.5 the treatment of disruptive behavioral symptoms in children with mg/day orally for the first 2 weeks and 1 mg/day for the rest of the autism and other PDDs. Patients needed to have a diagnosis of a study. Concomitant drugs were not permitted, except antiepileptic PDD as defined by the DSM-IV, and to also have a Childhood drugs for children with epilepsy. A total of 39 children completed Autism Rating Scale (CARS) total score of >30, with or without the study; 19 were given risperidone. Baseline characteristics were mental retardation. Exclusion criteria were any concomitant medisimilar between the two groups. Ninety-two percent of patients cal or psychiatric disorders, and a seizure disorder that was being had experienced irritability, and all children had some level of treated with more than one anticonvulsant. Medications to treat language impairment. Other symptoms at baseline were withdraw-EPS were discontinued, but could be used throughout the trial if al, aloofness, or inattention in 50% of patients, hyperactivity in EPS occurred. Risperidone oral solution was used in this study, 70% of patients, and 75% of patients had restricted patterns of and dosing was weight based. The maximum dose was 0.06 mg/ interests. kg/day. Seventy-nine children were randomized to receive either risperidone (n = 40) or placebo (n = 39). The diagnoses were as Twelve of 19 risperidone-treated patients displayed a response follows: autistic disorder (n = 55), Asperger's disorder (n = 12), (improvement of at least 20% from baseline on the CARS) comchildhood disintegrative disorder (n = 1), and PDD-NOS (n = 11).
pared with no children in the placebo group. On the Children's Fourteen children had normal IQ scores, ten had borderline IQ Global Assessment Scale, 17 of 19 risperidone-treated patients had scores, 20 had mild retardation, and 22 had severe retardation. The a response (increase from baseline of at least 20%), whereas only primary outcome was the change in the irritability subscale on the two placebo patients exhibited similar success. A 95% response ABC.
rate was seen with risperidone-treated patients on the Global By week 2, risperidone-treated patients had a statistically sigImpression of Parents survey, with 9 of 19 patients rated as nificant decrease in the irritability subscale score (p ≤ 0.001) 'improved to some extent,' and 9 of 19 of patients rated as compared with placebo and by week 8, risperidone-treated patients 'considerably improved.' Only one patient was reported as having improved by a mean of 12.1 points compared with 6.5 points in the a lower level of functioning. An analysis of the items on the parent placebo group (p ≤ 0.001). The risperidone-treated group also questionnaire revealed that risperidone significantly improved sodisplayed a statistically significant improvement in the other subcial responsiveness in 7 of 19 patients, non-verbal communication scales of the ABC; hyperactivity/non-adherence, inappropriate in 8 patients, decreased symptoms of hyperactivity in 7 patients, and improved aggression and irritability in 5 patients. However, titrated and dosed by an unblinded child psychiatrist. It is importhere was no benefit shown for risperidone with regard to restricttant to note that all patients in this trial were undergoing concured interests, emotional interaction, verbal communication, or rent applied behavior analysis therapy. The CARS was used as the speech. Adverse effects reported at a higher incidence for the primary outcome measure in this trial. A score of 30-37 is indicarisperidone-treated group were increased appetite, improved eattive of mild-to-moderate severity of symptoms, and a score of >37 ing habits, and weight gain, although these changes were not is indicative of severe autism symptoms. Of interest in this trial is statistically significant. All risperidone-treated patients experthat the risperidone-treatment group had a higher baseline CARS ienced regularization of sleep habits, daily feeding, and play score than the placebo recipients (37.6 ± 4 vs 33.3 ± 4.9). Howevroutines. Parents reported that the children were more easily er, this was accounted for when performing the statistical analysis. managed while taking risperidone. Three children experienced Risperidone-treated patients had a nonsignificantly greater imdyskinesias, but these were mild and transient and did not require provement in the overall CARS score than placebo-treated patients discontinuation from the trial. In the discontinuation phase, nine (-4.6 vs -1.8) from baseline to endpoint at 6 months. The average children experienced a relapse of disruptive behavior within 3 CARS score in the risperidone group did decrease from 'severely weeks of stopping risperidone therapy. Seven children continued autistic' to 'mildly to moderately autistic,' while classifications to have a lack of disruptive symptoms after discontinuing risperdid not change in the placebo group. However, the only subscale to idone therapy, and were considered to have consistent improveshow any significant improvement was the CARS Emotional ment. The other three children were considered to be stable after Response subscale. Other subscales, including symptoms such as discontinuation.
adaptation, fear and nervousness, anxiety, and socialization did not show improvement compared with placebo. Weight gain was 2.96 Troost et al. [36] conducted a 6-month open-label trial of risper-± 2.53kg in the risperidone group and 0.61 ± 1.10kg in the placebo idone (mean final dose 1.8 mg/day) in patients with PDDs folgroup. Transient sedation was also a common adverse event in lowed by an 8-week, double-blind, discontinuation phase. There risperidone-treated patients. Prolactin levels increased significantwere 36 children who entered the open-label phase. Twenty-four ly more in the risperidone-treatment group (33.38 ± 14.48 ng/mL of these children completed the first part of this study, were vs 11.11 ± 18.74 ng/mL) but no prolactin-related adverse events considered to be responders according to the CGI-I, and entered were reported. No EPS were reported. the double-blind discontinuation phase. Irritability, hyperactivity, self-injurious behavior, and social withdrawal scores on the ABC significantly improved over the 6 months. Baseline characteristics Open-Label Studies are only given for these 24 children. Six children had a diagnosis
There are nine open-label trials regarding the use of risperidone of autism spectrum disorder, two of Asperger's disorder, and 16 of in autism; [45] [46] [47] [48] [49] [50] [51] [52] [53] data are summarized in table III. Because of the PDD-NOS. Fifteen children had an average or above average IQ, open-label design, the large number of trials, and their similar seven had a borderline IQ, and only two had mild-to-moderate positive results, the open-label studies are summarized to a lesser mental retardation. The double-blind discontinuation phase inextent than the double-blind trials. volved one group continuing with risperidone, while the other had
The first open-label study on risperidone in children with PDDs their dose reduced by 25% every week for 3 weeks followed by was conducted by Fisman and Steele. [53] Thirteen of the 14 enplacebo for an additional 5 weeks.
rolled patients improved based on the Children's Global AssessEight of the 12 children in the placebo group relapsed versus 3 ment Scale. Behaviors that improved were agitation, anxiety, of 12 children receiving risperidone. However, a set definition of disruptive behaviors, and social awareness. Initial sedation was the relapse does not appear to have been predefined by the authors. most common adverse effect in this study. No EPS were reported Only the ABC irritability subscale showed a statistically signifiin this study either. cant difference at the end of the discontinuation phase (60% Rausch et al. [45] approached the use of risperidone differently increase in placebo patients, 14% increase in risperidone-treated than in other trials. The goal of their 12-week open-label study was patients). No withdrawal adverse effects were reported.
to determine if risperidone was effective for the 'negative sympLuby et al. [37] evaluated the use of risperidone in 23 preschool toms' of 13 children with Asperger's disorder. They proposed that children (aged 2.5-6 years) with autistic spectrum disorder in a 6-certain symptoms in Asperger's disorder are similar to negative month, double-blind, placebo-controlled trial. This is the youngest symptoms seen in other psychiatric illnesses, such as schizophrepatient population studied in clinical trials of AAs in autism.
nia. These symptoms include a lack of social interaction, lack of Dosing was lower than in other trials, with a mean starting and emotional reciprocity, depression, and a lack of speech. This study final dose of 0.5mg and 1.14 mg, respectively. Risperidone was used the Scale for the Assessment of Negative Symptoms (SANS), the Asperger's Syndrome Diagnostic Scale (ASDS), and the There was a statistically significant decrease in each of the assessment scales and their subcategories which included lanMontgomery-Åsberg Depression Rating Scale (MADRS) as their guage dysfunction, social behavior, maladaptive behavior, cognioutcome measures. Risperidone treatment was initiated at 0.5 mg/ tive dysfunction, sensorimotor dysfunction, and general dysfuncday with a final dosage range of 0.5-1.5 mg/day. Nine children tion. These results seem to contradict those of McDougle et al. (see completed the 12-week study.
the Double-Blind Studies section), [43] who reported no improve- (15); 5-19 1.8 mg/day CGI-I: VMI: n = 3; MI: n = 9;Y-BOCS: Aggression, impulsivity, al. [51] (1-4 mg/day) 15 at baseline vs 10.3 at 12wk repetitive behavior, sensory response Horrigan et al. [52] 4wk 6 (6) a ; 6-17 1 mg/day (0.5-1.5 CGI-I: VMI: n = 4; MI: n = 2 Aggression, self-injurious mg/day) behavior, explosivity, sleep, hyperactivity Fisman and 8wk, followed up 14 (10); 9-17 No mean given CGAS improvement by 1-2 levels Agitation, anxiety, Steele [53] to 14mo (0.75-1.5 mg/day) in all pts aggression, hyperactivity, temper outbursts a Five patients in this study were aged ≥18y, and were removed from the data analysis. CARS = Childhood Autism Rating Scale; CGAS = Children's Global Assessment Scale; CGI-I = Clinical Global Impression -Improvement (reported as no. of pts); CGI-S = Clinical Global Impression -Severity; CPRS = Children's Psychiatric Rating Scale; MI = much improved; Min I = minimally improved; pts = patients; SANS = Scale for Assessment of Negative Symptoms; VMI = very much improved; Y-BOCS = Yale-Brown Obsessive Compulsive Scale. ment in social and communication skills. However, unlike the considered responders. Sedation and weight gain (average 3.5kg) patients in the latter study who all had a diagnosis of autism, were again the most common adverse events reported. patients in this study had Asberger disorder. Perhaps the severity Findling et al. [50] conducted a pilot study of risperidone in six of illness may play a role in the response. Weight gain was again a autistic children over 8 weeks. All children completed the study, common adverse effect in this study (average increase of 5.1kg).
and had improvements in restlessness, tantrums, irritability, fearOther adverse effects included sedation and EPS (three cases); one fulness, and aggression. There was also improvements in their of the latter patients withdraw from the study due to akathisia CPRS scores and CGI-I ratings. Again, sedation and weight gain while the other two cases were not severe enough to warrant were the most common adverse events. There was one case of EPS discontinuation of treatment.
in this study. Malone et al. [46] conducted a study of 22 autistic children over
McDougle et al. [51] studied risperidone in 18 children during a two phases. In the first phase, which was 1 month in duration, the 12-week open-label trial. Eleven patients had a diagnosis of autischildren received risperidone at a mean dosage of 1.2 mg/day. tic disorder, three had Asperger's disorder, one had childhood Thirteen children were considered responders at the end of that disintegrative disorder, and three had PDD-NOS. Risperidone was month and continued on for a 6-month treatment period. At the end initiated at 0.5 mg/day and increased by 0.5mg increments. At the of the second phase, ten patients were considered responders based end of 12 weeks, 12 patients were considered responders based on on the Children's Psychiatric Rating Scale (CPRS) and the CGI-I.
their CGI-I, with improvements in aggression, impulsivity, and The mean dosage at the end of the second phase was 1.8 mg/day. repetitive behavior. Weight gain occurred with an average increase The most common adverse events were sedation, appetite inof 7.9kg, higher than seen in other trials. Sedation was also a crease, and weight gain averaging 3.3kg. None of the children commonly reported adverse event. Two patients experienced a experienced dyskinesias in the second phase; however, two chiltransient increase in heart rate 1-2 hours after drug intake, but no dren did develop withdrawal dyskinesias, which resolved within other complications were seen. 2-3 weeks after discontinuation.
One of the earlier studies on risperidone examined 11 autistic patients.
[52] Six of these patients were aged ≤17 years. Only the Diler et al. [47] investigated risperidone (mean dose 1.5 mg/day) results for those six patients are discussed here; all had moderatein 20 autistic children in a 6-month open-label study. Sixteen to-severe mental retardation. Five of these children finished the children completed the study, and 13 were considered responders 4-week open-label trial with four having marked improvement based on the CGI-I. The patients also had a significant reduction in based on the CGI-I, and one having moderate improvement. their CARS scores at the end of 6 months. The most frequent Conner scale scores also improved in these patients; a decrease in adverse events were again sedation and weight gain; however, aggression was seen. However, this small study allowed concomionly two patients experienced weight gain, and both gained <10% tant medications, and the four patients who had marked improveof their weight. There was one case of akathisia in this study. ment were also receiving other treatments (clonidine, valproic Zuddas et al.
[48] conducted a study on 11 children and adolesacid, clomipramine, cyproheptadine, and propranolol). Four pacents for 6 months. Nine children had a diagnosis of autism, and tients also experienced weight gain. No EPS were reported. two children were diagnosed with PDD-NOS. Risperidone was started at 0.5 mg/day and titrated according to the response. Ten
Olanzapine
patients were considered responders at the end of 6 months. Along with sedation and weight gain, there were also two cases of There are three trials involving the use of olanzapine in children dystonia and amenorrhea each. The higher mean dose (2.7 mg/ with PDDs that match the criteria for this review; a total of 48 day) used in this study than in the other open-label trials could patients were involved and results are summarized in tables II and account for the increased incidence of those adverse effects.
IV. [38, 54, 55] A fourth trial by Potenza et al. [56] was not reviewed Patients could elect to receive risperidone and to be followed for 6 because it involved both children and adults and it was not additional months. Patients who elected to continue receiving possible to single out the pediatric data. risperidone were still stable at the end of 12 months. Patients who
The only double-blind, placebo-controlled trial of olanzapine in discontinued therapy before 12 months experienced a relapse in autism was conducted by Hollander et al. [38] It was a small trial their behavioral symptoms.
with only 11 patients (six in the olanzapine arm, five in the placebo Nicolson et al. [49] conducted a 12-week open-label study in ten arm). Children in the active treatment arm were started on autistic children. Patients were started on risperidone 0.5 mg/day. olanzapine 2.5mg every other day if <40kg in bodyweight, or Based on the CGI-I and the CPRS, eight of ten children were 2.5mg every day if >40kg. The dosage was increased 3 days later to 5 mg/day, and increased in 5mg increments weekly to a maxisimilar statistically significant improvements in the CPRS autism mum of 20 mg/day. factor; both treatment options improved all the items listed included in the autism factor with the exception of underproductive The CGI-I was the primary outcome measure, with three of six speech. The olanzapine-treatment group showed a statistically children in the olanzapine-treatment group meeting the a priori significant improvement in the CPRS anger/uncooperativeness criteria for a responder. One of the five children in the placebo factor and the CPRS hyperactivity factor, while the haloperidolgroup was considered a responder. However, there was no statistitreatment group did not. Neither of the two treatment groups cal improvement in any of the symptom scales, including the CYshowed improvement in the CPRS speech deviance factor. Over-BOCS and the Overt Aggression Scale -Modified, which evaluall, both treatment options showed improvement in this patient ated aggression and irritability. Weight gain was the most common population after 6 weeks, with olanzapine being better than adverse event seen in this trial, with the average weight gain in the haloperidol for anger/uncooperativeness and hyperactivity. olanzapine treatment arm being 3.4 ± 2.2kg and 0.7 ± 0.7kg in the placebo group (p = 0.028). Four of six children treated with
The most common adverse effect seen with olanzapine treatolanzapine gained more than 7% of their weight. Increased appement was sedation upon initiation of the medication and weight tite and sedation were also common adverse events.
gain. All six patients receiving olanzapine gained at least 2.5kg (range 2.7-7.2kg). Only two patients in the haloperidol-treatment Malone et al. [54] conducted the only active comparator study to group gained over 2.5kg, and the range was from a 2.5kg loss to a date regarding the use of AAs in PDDs. They compared 4kg gain. As rated by the Neurologic Rating Scale (NRS) and the olanzapine versus haloperidol in an open-label 6-week trial.
AIMS, one haloperidol recipient experienced an EPS; EPS were Twelve children were enrolled and were randomly distributed into not reported in the olanzapine group. Triglycerides and blood either treatment group; the two treatment groups had similar glucose levels were not monitored in this trial. demographics. Eleven of the patients met the criteria for diagnosis of autistic disorder and one had a diagnosis of PDD-NOS. Ten of Kemner at al.
[55] conducted a 12-week open-label trial of 25 the patients had moderate-to-severe mental retardation. Patients children with autism or PDD-NOS, the majority of whom were who were being treated concomitantly with other psychotropic male (exact numbers not given). Only three children were identimedications or had a history of previous response to treatment fied as having mild mental retardation; the remaining children had with olanzapine or haloperidol were excluded from this study.
none. Patients were started on 2.5 mg/day of olanzapine. The final Olanzapine was initiated at 2.5mg every other day for children dosage ranged from 2.5 to 20 mg/day, with a mean dosage of ≤40kg in bodyweight, and 2.5 mg/day if >40kg. Increases could be 10.7 mg/day. The CGI-I was used as the outcome measure to made in increments of 2.5-5 mg/week. Haloperidol was dosed determine overall response. A child had to have a rating of at least starting at 0.25 mg/day for children ≤40kg, and 0.5 mg/day if 'much improved' to be considered a responder. The ABC was >40kg. Increases could be made in increments of 0.5-1 mg/week. used to determine behavioral symptom improvement; the five The final dosage ranges used in this trial were 5-10 mg/day for behaviors measured were irritability, lethargy, stereotypy, hyperolanzapine, and 0.5-2.5 mg/day for haloperidol. activity, and excessive speech. The primary outcome measure was the CGI-I. In the olanzapine Of the 22 children who completed the study, only three were group, one child was rated as 'very much improved,' four were rated as 'much improved' on the CGI-I, and therefore met the a rated as 'much improved,' and one as 'minimally improved.' In priori criteria of response. Ten children were rated as 'minimally the haloperidol group, one child was rated as 'very much imimproved' and nine children showed no improvement. The behaproved,' two were rated as 'much improved,' and three as 'miniviour measures on the ABC that were statistically improved from mally improved.' This difference between the two treatment opbaseline to endpoint were irritability, hyperactivity, and excessive tions was not statistically significant (p = 0.494). Overall both speech; however, this improvement may not be clinically signifitreatment options were efficacious in improving overall illness cant. Safety data were collected for all 25 children who entered the symptoms. The CPRS was used as a secondary outcome measuretrial. There were 14 reported cases each of weight gain, general ment. Four categories were derived from different CPRS weakness, and increased appetite. The average weight gain for the items: (i) autism factor (social withdrawal, stereotypic motions, 14 children who reported it as an adverse event was 5.8kg. abnormal object relations, unspontaneous relation to examiner, Somnolence was reported in six of the children. Evidence of EPS, underproductive speech); (ii) anger/uncooperativeness factor (anincluding akathisia, joint rigidity, gait abnormalities, and tremor gry affect, labile affect, negative, uncooperative); (iii) hyperactiviwere reported as having occurred in ten cases. It is not clear ty factor (fidgetiness, hyperactivity); and (iv) speech deviance whether this was in ten different children or not. However, EPS factor (speech deviance, low voice). Both treatment groups had resolved upon lowering of the dose.
In summary, when compared with the data for risperidone, descending order, aggression, irritability, over-activity, social olanzapine results do not appear as robust. There is much more withdrawal, and tantrums. An a priori response definition was data to support the use of risperidone; however, more controlled determined to be a CGI-I of 'much improved' or 'very much trials with olanzapine may show further significant improvement.
improved' by the end of the 12-week trial. Quetiapine was initiatHowever, at this time, due to its adverse effect profile, particularly ed at 25mg twice daily and increased to a target dosage of 150mg its high incidence of weight gain seen in these trials, olanzapine twice daily. Doses could be increased after that based on the should be reserved as a second-line treatment option for children clinician's discretion. The final daily dose of quetiapine ranged with PDDs. from 100 to 450mg (mean of 291.7mg). Three patients did not complete the trial; one was lost to follow-up, and the other two discontinued because of increased aggression/agitation, and drow-
Quetiapine
siness, respectively. There were two open-label trials of quetiapine that matched the Only two patients were responders; three were rated as 'minicriteria for review; results are summarized in table IV. [57, 58] There mally improved,' two had no change, and one was rated as 'much was a total of 15 patients in both of these studies.
worse' according to the CGI-I. Only the two patients who were Martin et al. [57] conducted a pilot 16-week, prospective trial of responders agreed to continue receiving quetiapine. The most quetiapine in six children with a diagnosis of autistic disorder; all common adverse effects reported by parents were sedation (n = 7) had some degree of mental retardation. Only one of the patients and weight gain (n = 5). Four parents reported increased agitation had received prior treatment with an AA (risperidone); this patient and two reported aggression. The AIMS and the NRS were also underwent a 2-week washout period before the initiation of queused to assess the safety of quetiapine; no differences from basetiapine. For all patients, quetiapine was started at 25 mg/day at line were found at study end. bedtime and increased by as much as 100 mg/week based on the The findings from these two studies, albeit with small patient clinician's judgment. At study end the dosage range varied from numbers, do not seem to support the use of quetiapine in children 100 to 350 mg/day. Primary outcome measures in this trial includwith autistic disorder. Only 4 of 15 patients were considered to ed the irritability subscale of the ABC and the CGI-I. Response have responded to treatment with quetiapine. This drug may be was defined as a score or 'much improved' or 'very much imbeneficial in a small subset of patients, but until more controlled proved' on the CGI-I. Only two patients completed the 16-week clinical trials are performed there is little evidence to support the trial and were the only patients to be categorized as responders.
use of quetiapine in PDDs. The other four patients withdrew because of a lack of symptom improvement along with inability to tolerate the medication; sedation was the reason for discontinuation in three patients and the
Ziprasidone
fourth patient had a probable seizure. There was no statistical There is only one published, prospective, open-label trial of improvement seen in the irritability subscale of the ABC. The Rziprasidone in PDDs; results are summarized in table IV. FRLRS and CY-BOCS were also performed at baseline and study
McDougle et al. [59] examined the use of ziprasidone in 12 children end with no significant changes seen in either. Four patients and adolescents with PDDs; the patients ranged from 8 to 20 years experienced weight gain ranging from 0.9 to 8.2kg.
of age, with two patients being >17 years old. The data from the The second trial of quetiapine was a 12-week open-label study latter two patients have been removed for the purposes of this of nine patients with an axis I diagnosis of autistic disorder. [58] review. Of the remaining ten patients, seven had a diagnosis of There was no mention of mental retardation status. Inclusion autism disorder and three had a diagnosis of PDD-NOS. All but criteria were a CARS score of ≥30, indicating mild-to-moderate one of the patients had mental retardation ranging from mild to severity of symptoms, and a CGI-S score of at least moderate severe (mild, n = 4; moderate, n = 4; severe, n = 1; none, n = 1). severity. Patients with any other significant medical, neurologic, Patients were not excluded if they had other axis I diagnoses. or psychotic disorder were excluded as were patients who received
There was no set duration of treatment; the only criterion was that an antipsychotic, anticonvulsant, or tricyclic antidepressant 1 the patients received ziprasidone for at least 6 weeks. The mean week prior to study initiation. However, other psychotropic mediduration of treatment was 14 weeks, with a range of 6-30 weeks. cations (clonidine, stimulants, fluoxetine, sertraline, and busAn a priori definition of response was set as a CGI-I score of pirone) were allowed during the study. Outcome measures includ-'much improved' or 'very much improved.' Ziprasidone was ed the CPRS, the ABC, and the CGI-I scale. Two target symptoms started at 20mg at bedtime and given twice daily, and was inwere also selected for each patient for which quetiapine was being creased by 10-20 mg/week. The final mean daily dose of prescribed. These symptoms varied per patient, and included, in ziprasidone was 60mg with a range of 20-120mg.
At the end of the study, five of ten patients met the criteria for or 'very much improved.' Aripiprazole was initiated at 5-10mg at 'responder' ('much improved'). Three patients were rated as havbedtime based on the clinician's discretion. The mean dosage of ing no change, one was 'minimally improved,' and one was rated aripiprazole at the end of the study was 12 mg/day (range of as 'much worse' based on the CGI-I. Nine patients in this study 10-15mg). All patients received aripiprazole for at least 20 weeks, had previously been treated with another AA (risperidone, and a maximum of 24 weeks. olanzapine, quetiapine, thioridazine) and had discontinued due to All five patients met the a priori definition for being a respondinadequate response or weight gain. In five patients who were still er. The symptoms that seemed to respond best to treatment were receiving another AA at baseline, it was slowly tapered over a 4-aggression, agitation, and self-injurious behavior. Mild sedation week period while ziprasidone was titrated. This did not seem to was the most common adverse effect. No patients experienced affect the outcome of the study, as only two patients who were EPS. receiving another AA at baseline were responders at endpoint. The
There are recently presented data [61] showing improvement in symptoms that were reported to have responded the most were 12/13 aripiprazole-treated PDD children over 14 weeks. The 12 aggression, irritability, self-injurious behavior, and mood instabiliresponders, aged 5-17 years, were categorized as responders ty. Sedation was the most common adverse effect experienced.
based on a CGI-I of 'much improved' or 'very much improved' Four of the ten patients experienced no adverse effects at all.
and at least a 25% improvement on the ABC-Irritability subscale. Baseline ECGs were performed on all the patients and were
The mean baseline ABC-Irritability score was 29.5 and decreased normal. The possible QT prolongation associated with to a mean of 6.8 at week 14. The authors state that this was a ziprasidone [62] is usually not clinically significant unless the pasignificant change based on statistical tests, but no exact measures tient has a prolongated QT interval at baseline; therefore, no were given. Aripiprazole was initiated at 1.25 mg/day in all follow-up ECGs were performed. No cardiovascular adverse efpatients and increased to a maximum or 15 mg/day. No patients fects were observed during the study. Weight gain was seen in experienced EPS. An average weight gain of 1.2kg was seen only one patient. The mean weight change was -2.7kg (range (range -0.95 to +3.5kg). Enrollment for this study is ongoing. -15.9 to +2.7 kg). This is most likely due to the fact that eight Aripiprazole might be an option when children cannot tolerate patients had significant weight gain from their previous antipsyother AAs because of weight gain or other adverse effects; howevchotic treatment, rather than ziprasidone having weight-reducing er, the data are limited at this time. More rigorous and controlled properties.
trials are needed to verify the results from these small studies. Data on ziprasidone in PDDs are limited due to the small Aripiprazole may prove to be unique in the treatment of PDD sample size and nature of the only published trial; however, it does because of its mechanism of action as a partial dopamine agonist. appear promising. Larger and more controlled clinical trials are warranted to determine if ziprasidone is truly efficacious for 2.1.6 Clozapine symptom control in autistic children. Also more trials would help
The data on the use of clozapine in PDDs are limited to two to determine if there is a dose-response relationship, considering published case reports involving a total of four patients with that the dose in the trial reviewed here was relatively low. [59] autistic disorder. [63, 64] Although these do not match the criteria for Currently, ziprasidone is an option for patients who have not this review, it is important to mention them since they are the only responded to other AAs for which there is better evidence, or have data available. The patients included three boys aged 8, 8, and 17 gained significant weight from their previous treatment.
years, and one 12-year-old girl. One of the boys had severe mental retardation; the mental condition of the other boys was not men- were reported. The girl demonstrated some initial improvement amined five male patients (aged 5-18 years) diagnosed with a (maximum dose of 450 mg/day) but after 5 months had returned to PDD; results are summarized in table IV.
[60] Four had a diagnosis her baseline condition. The adverse effects reported were sedation, of autistic disorder, and one was diagnosed with Asperger's disorenuresis, sialorrhea, and constipation. None of the children develder. Concomitant psychotropics were allowed, and two patients oped neutropenia. received methylphenidate and clomipramine, respectively. All patients had recently discontinued another AA (risperidone, Based on the limited evidence, the use of clozapine in PDD olanzapine, or quetiapine) due to either ineffectiveness or weight should be limited to severely refractory cases. Caution should be gain. Response was defined as a CGI-I rating of 'much improved' used when prescribing clozapine because of its risk of agranulocy- Malone et al. [54] 12 (8); 4-12 OLZ: 7.9 mg/day OLZ: VMI: n = 1; MI: n = 4; Anger, uncooperativeness, (6wk) (5-10 mg/day) Min I: n = 1 hyperactivity HLP: 1.4 mg/day HLP: VMI: n = 1; MI: n = 2; (0.5-2.5 mg/day) Min I: n = 3
Kemner et al. [55] (12wk) 25 (not given); 6-16 OLZ 10.7 mg/day MI: n = 3; Min I: n = 10; no Irritability, hyperactivity, excessive (2.5-20 mg/day) change: n = 9 speech Martin et al. [57] (16wk) 6 (6); 6-15 QTP 225 mg/day VMI: n = 1; MI: n = 1; no No significant improvements (100-350 mg/day) change: n = 1; Min W: n = 2; MW: n = 1
Findling et al. [58] [59] (20-120 mg/day) change: n = 3; MW: n = 1 instability, self-injurious behavior
Stigler et al. [60] (20-24 wk; 5 (5); 5-18 ARIP 12 mg/day VMI: n = 2; MI: n = 3 Aggression, agitation, self-injurious average 22 wk) (10-15 mg/day) behavior
Stigler et al. [61] (14wk) 13 (10); 5-17 ARIP 7.5 mg/day VMI or MI: n = 12 (exact Irritability (2.5-15 mg/day) numbers not given)
a Two patients in this study were >18 years of age and were removed from this analysis.
CGI-I = Clinical
Global Impressions-Improvement (reported as no. of pts); HLP = haloperidol; LFU = lost to follow-up; MI = much improved; Min I = minimally improved; Min W = minimally worse; MW = much worse; pts = patients; VMI = very much improved; wk = week.
tosis and its effect on the seizure threshold. The frequent monitorpharmacokinetic parameters between children and adults, and ing and blood sampling make it inconvenient for use in children.
therefore did not recommend any dosing changes in children. Of interest, in a study of aripiprazole, the starting dose had to be decreased because the first four children enrolled reported vomit-
Pharmacokinetics of Atypical Antipsychotics
ing and somnolence. [70] According to this study, aripiprazole may in Children be better tolerated in children if started at a dosage of 2.5 mg/day for at least 2 days, and then titrated over 2 weeks to the target dose. Several studies have examined the pharmacokinetics of AAs in children; [65] [66] [67] [68] [69] [70] [71] however, only one deals specifically with PDD.
Proposed Mechanism of Action of
Casaer et al. [65] conducted the only single-dose risperidone Atypical Antipsychotics pharmacokinetic study in children (n = 6, 3-7 years of age) with a PDD. Oral doses were 0.015 mg/kg for three of the children and
The pathophysiology of autism is not completely understood. It 0.03 mg/kg for the other three. The peak plasma concentrations of is likely a heterogeneous disorder with a multifactorial etiology. risperidone and its main metabolite, 9-hydoxyrisperidone, were Sections 2.3.1 to 2.3.3 discuss the possible relationship between proportionally similar to those seen in adults. However, in all six the three neurotransmitters serotonin, dopamine, and norechildren, the time to the maximum plasma concentration was pinephrine (noradrenaline) and the observed clinical response to shorter than that in adults (1 hour post-dose); this is similar to the AA treatment for autism. The observed efficacy of AAs may be characteristics of extensive metabolizers. Since the area under the related to their ability to affect more than one neurotransmitter plasma concentration-time curve was not affected, the clinical system. significance of this finding may be negligible. The half-life of the metabolite was 30-35% lower than in adults also. Because no
Serotonin
other studies have been published confirming or refuting this data,
The finding of hyperserotoninemia in a significant percentage a solid conclusion cannot be deduced.
of individuals with autism suggests that this neurotransmitter may The other literature reviewing the pharmacokinetics of AAs in be a potential target for pharmacotherapy. [72] [73] [74] Increased platelet children [66] [67] [68] [69] [70] [71] failed to show any significant differences in serotonin has been observed for over 40 years in patients with
Norepinephrine (Noradrenaline)
autism; however, since it has not been identified in all patients Elevated norepinephrine plasma levels have also been reported with autism, its role in this disorder is yet to be fully underin autism. [73] Therefore, norepinephrine dysregulation could be a stood. [73, 75] The role for serotonin as an immunomodulator and factor in certain aspects of the symptoms of autism. However, thus affecting immunity has also been suggested. [76] The cause of psychostimulants and clonidine (noradrenergic agents) may offer the hyperserotoninemia has not been identified. Increased synthecertain symptomatic improvements, through different mechanisms sis, dysregulation in uptake, and receptor-mediated controls of of action, in terms of inattention in some patients, or aggression serotonin have all been implicated. Since the selective serotonin and irritability, respectively, in others. reuptake inhibitors and AAs have demonstrated a relatively conSome AAs such as clozapine, risperidone, and quetiapine have sistent level of efficacy in treating certain features of autism and α-1 and α-2 receptor antagonism as part of their pharmacologic they are both serotonergic in their mechanisms of action, [44, 77, 78] profile and these properties may contribute, to an unknown degree, there is clinical support for a serotonin dysregulation component to their observed efficacy. [73, 91] of autism. [79] [80] [81] Lending some support to the efficacy and relationship of the A genetic polymorphism has been identified for the serotonin AAs to more than one, if not all, of these neurotransmitter systems transporter (5-HTTLPR) in patients with autism, lending further is the US FDA approval in October 2006 of risperidone, the first support for the use of serotonergic agents. [82, 83] Genetic abnormaliagent for the treatment of irritability and aggression in autism. ties on the chromosome 7q31 region may be associated with This agent has the combined qualities of serotonin, dopamine, and language disorders, but they are also related to the serotonin 2A norepinephrine receptor antagonism. It thus supports the proposireceptor (5HT2A) HTR2A gene. [84] Dysregulation of the 5HT2A tion that a multi-transmitter dysregulation is occurring in autism, receptor and the subsequent blockade of that receptor by AAs may or at the least, that these systems are interrelated and therefore support the outcomes observed in clinical trials with these agents targeting one or more of these neurotransmitters may improve showing selected benefits in autism. [85] [86] [87] certain symptoms of autism. [92] The strong serotonin receptor antagonism demonstrated by most AAs and the recognized efficacy of members of this class of agents, such as risperidone, supports the ongoing hypothesis of 3. Discussion serotonin dysregulation as a factor in some patients with autism. [31, 77, 78] Based on the reviewed literature, AAs can play a role in the treatment of children with PDDs. They can be used to control
Dopamine
symptoms such as aggression, irritability, hyperactivity, and some stereotypic behavior. However, there is more favorable evidence Dopamine neurotransmitter dysregulation may also occur in for the use of risperidone than for other AAs. autism. Dopamine is associated with certain functions including attention, motivation, and planning. If these areas of cognition are Risperidone has been studied in five double-blind, placeboimpaired and certain behaviors occur such as aggression or irritacontrolled trials and nine open-label trials all with similar results bility, then treatment with antipsychotic agents may result in of improvement in symptoms. One open-label trial has shown that modest improvements. [83] Dopamine antagonism is a principle olanzapine is as effective as haloperidol, but other open-label trials mechanism of many antipsychotics and may be part of their ability have failed to show efficacy with this agent in PDDs. Quetiapine to reduce agitated and aggressive behaviors. The dopamine D2
does not seem to be effective either. This may be due to its fast receptor is a common target of both older antipsychotics and disassociation at dopamine receptors. There is only a small amount newer atypical ones. The AAs are usually more potent at 5HT2A of data for ziprasidone and aripiprazole but these data are promisantagonism than D2 receptor antagonism and this may contribute ing. More trials are warranted with these two medications. The use to their lower risk for extrapyramidal adverse effects. [78] of clozapine is limited because of its incidence of agranulocytosis and its potential for lowering the seizure threshold. Blockade of the D2 receptor in mesolimbic areas may reduce symptoms of aggression and agitation; however, this antagonism
The adverse effect of weight gain is a concern with AAs. The may not be a beneficial action in the frontal cortex. Increasing clinical trials with risperidone, olanzapine, and quetiapine all dopamine activity in the pre-frontal cortex may be a preferential showed significant weight gain, with weight gain being slightly benefit of the atypical agents over the older conventional agents.
greater with olanzapine. Ziprasidone and aripiprazole did not This occurs either by selectivity for other dopamine receptors, cause weight gain, and some patients lost weight while receiving such as D1 or D4 receptors, or by indirect enhancement or efflux these medications. Although this may have been due to discontinuthrough serotonin antagonism. [88] [89] [90] ation of a previous AA rather than to a property of ziprasidone or aripiprazole, these agents do not seem to cause the same amount of
